118 related articles for article (PubMed ID: 19430282)
1. Diagnostic and therapeutic challenges.
Yang S; Borirakchanyavat S; Chan-Kai BT; Stout JT; Fu AD
Retina; 2009 May; 29(5):708-14. PubMed ID: 19430282
[No Abstract] [Full Text] [Related]
2. Management of Coats disease with bevacizumab in 2 patients.
Venkatesh P; Mandal S; Garg S
Can J Ophthalmol; 2008 Apr; 43(2):245-6. PubMed ID: 18347637
[No Abstract] [Full Text] [Related]
3. Juxtafoveal telangiectasias.
Querques G; Delle Noci N
Ophthalmology; 2008 Sep; 115(9):1636; author reply 1636. PubMed ID: 18762079
[No Abstract] [Full Text] [Related]
4. Intravitreal bevacizumab (Avastin) in idiopathic retinitis, vasculitis, aneurysms and neuroretinitis.
Akesbi J; Brousseaud FX; Adam R; Rodallec T; Nordmann JP
Acta Ophthalmol; 2010 Mar; 88(2):e40-1. PubMed ID: 19508455
[No Abstract] [Full Text] [Related]
5. Combined intravitreal bevacizumab and argon laser treatment for Coats' disease.
Cackett P; Wong D; Cheung CM
Acta Ophthalmol; 2010 Mar; 88(2):e48-9. PubMed ID: 19500078
[No Abstract] [Full Text] [Related]
6. Intravitreous ranibizumab as treatment for macular telangiectasia type 2.
Lira RP; Silva VB; Cavalcanti TM; de Souza AC; Pinto AP
Arch Ophthalmol; 2010 Aug; 128(8):1075-8. PubMed ID: 20697014
[No Abstract] [Full Text] [Related]
7. Combined photodynamic therapy and intravitreal bevacizumab as primary treatment for subretinal neovascularization associated with type 2 idiopathic macular telangiectasia.
Rishi P; Rishi E; Shroff D
Indian J Ophthalmol; 2009; 57(3):241-2. PubMed ID: 19384026
[No Abstract] [Full Text] [Related]
8. Findings in fluorescein angiography and optical coherence tomography after intravitreal bevacizumab in type 2 idiopathic macular telangiectasia.
Charbel Issa P; Holz FG; Scholl HP
Ophthalmology; 2007 Sep; 114(9):1736-42. PubMed ID: 17822979
[TBL] [Abstract][Full Text] [Related]
9. Elevated vascular endothelial growth factor level in Coats' disease and possible therapeutic role of bevacizumab.
He YG; Wang H; Zhao B; Lee J; Bahl D; McCluskey J
Graefes Arch Clin Exp Ophthalmol; 2010 Oct; 248(10):1519-21. PubMed ID: 20379736
[TBL] [Abstract][Full Text] [Related]
10. Resolution of macular edema in Coats' disease with intravitreal bevacizumab.
Entezari M; Ramezani A; Safavizadeh L; Bassirnia N
Indian J Ophthalmol; 2010; 58(1):80-2. PubMed ID: 20029156
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic and Therapeutic Challenges.
Badami K; Sultana A; Sinha B; Ijeri R; Jayadev C; Tsang SH
Retina; 2015 Sep; 35(9):1911-8. PubMed ID: 26090898
[No Abstract] [Full Text] [Related]
12. Diagnostic and Therapeutic Challenges.
Corvi F; Lattanzio R; Miserocchi E; Querques L; Bandello F; Querques G; Croft DE; Wykoff CC
Retina; 2016 Nov; 36(11):2239-2245. PubMed ID: 27322945
[No Abstract] [Full Text] [Related]
13. Intravitreal bevacizumab for foveal detachment in idiopathic perifoveal telangiectasia.
Maia OO; Bonanomi MT; Takahashi WY; Nascimento VP; Takahashi BS
Am J Ophthalmol; 2007 Aug; 144(2):296-9. PubMed ID: 17659962
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal bevacizumab in vascular pigment epithelium detachment as a result of subfoveal occult choroidal neovascularization in age-related macular degeneration.
Ach T; Hoeh AE; Ruppenstein M; Kretz FT; Dithmar S
Retina; 2010 Oct; 30(9):1420-5. PubMed ID: 20543764
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal bevacizumab compared with photodynamic therapy with verteporfin for group 2a parafoveal retinal telangiectasis.
Windisch R; Kozousek V
Can J Ophthalmol; 2008 Aug; 43(4):489-90. PubMed ID: 18711474
[No Abstract] [Full Text] [Related]
16. Intracameral bevacizumab in the treatment of neovascular glaucoma and exudative retinal detachment after brachytherapy in choroidal melanoma.
Vásquez LM; Somani S; Altomare F; Simpson ER
Can J Ophthalmol; 2009 Feb; 44(1):106-7. PubMed ID: 19169330
[No Abstract] [Full Text] [Related]
17. The article by Kovach and Rosenfeld.
Charbel Issa P; Holz FG; Scholl HP
Retina; 2009 May; 29(5):717; author reply 717-8. PubMed ID: 19430284
[No Abstract] [Full Text] [Related]
18. Optical coherence tomography-measured pigment epithelial detachment height as a predictor for retinal pigment epithelial tears associated with intravitreal bevacizumab injections.
Chan CK; Abraham P; Meyer CH; Kokame GT; Kaiser PK; Rauser ME; Gross JG; Nuthi AS; Lin SG; Daher NS
Retina; 2010 Feb; 30(2):203-11. PubMed ID: 19952998
[TBL] [Abstract][Full Text] [Related]
19. Coats' disease: treatment with intravitreal bevacizumab and laser photocoagulation.
Stergiou PK; Symeonidis C; Dimitrakos SA
Acta Ophthalmol; 2009 Sep; 87(6):687-8. PubMed ID: 18976310
[No Abstract] [Full Text] [Related]
20. Intravitreal bevacizumab (Avastin) for subretinal neovascularization secondary to type 2A idiopathic juxtafoveal telangiectasia.
Mandal S; Venkatesh P; Abbas Z; Vohra R; Garg S
Graefes Arch Clin Exp Ophthalmol; 2007 Dec; 245(12):1825-9. PubMed ID: 17345090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
